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Introduction
Preimplantation genetic diagnosis (PGD) is the procedure for genetically analyzing embryos, after an in-vitro fertilization (IVF),
in order to select the healthy ones for uterine transfer. PGD is a current option for couples with a risk of transmitting genetic
disorders or to improve the chance of conception. The development of some embryo manipulation procedures are facilitating
the utilization of PGD techniques (e.g.: ICSI, cryopreservation or vitrification, embryo biopsies…). Although the current methods
for PGD, including PCR and FISH, have been widely used to effectively diagnose many genetic disorders, they have limitations
in characterizing certain types of genetic conditions and cannot provide a genome-wide approach. Whole genome amplification
(WGA) techniques have provided the adoption of microarrays for a genomic assessment in PGD/PGS. Nevertheless, advances
in DNA sequencing are suggesting the possibility to finally introduce next-generation sequencing (NGS) technologies in the
PGD/PGS programs in a near future.
Acronyms: PGD, preimplantation genetic diagnosis; PGS, preimplantation genetic screening; IVF, in vitro fertilitsation; ICSI, intracytoplasmic sperm injection;
PCR, polymerase chain reaction; FISH, fluorescent in situ hybridization, WGA, whole genome amplification; NGS, next-generation sequencing; CNV, copy
number variation; ADO, allele drop out; LOH, loss of heterozygosity; SNP, single nucleotide polymorphism.
Classical techniques Microarrays
Indications PCR FISH aCGH SNP-array NGS
Sex selection (social or X-linked) Yes Yes* Yes Yes Yes
Aneuploidy screening Yes Yes*; locus 
specific Yes*; generic Yes; generic Yes; generic
DNA copy-number aberrations Yes Yes*; locus 
specific Yes*; generic Yes; generic Yes; generic
Family-specific design  time consuming Not de novo Only targeted, not genomic analysis
PCR FISH
Detection of single-gene disorders
Aneuploidy screening and CNV (by qPCR)
Causal mutations (+ linkage markers)
Better outcome by multiplex PCR with WGA
Risk of errors by ADO or homologous recombination
Risk of contamination
Genotype millions of known SNPs
Reduce risk of bias due to WGA artifacts
Detects LOH
Reconstruct haplotypes for carriers of 
single-gene or balanced rearrangements 
(by linked SNPs in the family)
Available genotype from parents and a 
close relative needed
Genome-wide analysis for aneuploidy screening and CNV
WGA allows PGD by microarrays
High resolution, rapid and simple procedure
Not mitochondrial
Not de novo base mutation
aCGH SNP-array
Risk of bias due to 
WGA artifacts (ADO, 
chimeric DNA 
molecules)
CNV and aneuploidy 
screening (few 
chromosomes)
Sex selection for X-linked 
diseases
Few coloured probes
Not for balanced rearrangements
Difficulties with multiple complex 
rearrangements
Not useful with single blastomeres
Figure 1. PGD procedures from three different embryo development stages. Yan, Li Ying et al. (2014) 
Carriership of balanced 
chromosome rearrangements No No No Yes Yes
Single-gene disorder Yes*; family 
specific No No Yes; generic Yes; generic
De novo segmental copy-number 
aberrations No No Yes; generic Yes; generic Yes; generic
De novo base mutations No No No No Yes; generic
Mitochondrial mutations Yes*; family 
specific No No No Yes
Next-Generation Sequencing
Conclusions
Figure 2. WGA is required before any genome-wide genetic analysis in PGD. There are still bias due to incomplete coverage, GC bias,
chimeric DNA molecules, ADOs, preferential allelic amplifications and nucleotide copy errors. No single WGA method delivers an unbiased
representation of a cell’s genome or is best across all criteria and subsequent applications. Van der Aa, Niels et al. (2013)
Classical methods for PGD will be gradually replaced by the introducion of affordable tecniques that allow a thorough genome-wide analysis for
almost every type of genetic alteration. Although NGS techniques are subject to constant ongoing refinements, the sequncing cost has drastically
decreased and they show many advantages over PCR, FISH and microarray-base protocols, before its introduction in PGD some challenges must
be overcome. Further advances in NGS technologies, coupled with improved embryo manipulation and DNA amplification methods, and the
development of new affordable platforms and finding new ways to reduce costs, will favor the adoption of NGS in PGD/PGS programs in a near
future.
Second-generation NGS methods
Template 
preparation 
(DNA, cDNA)
Massively 
parallel 
clonal 
amplification
Sequencing 
and 
alignment of 
short reads
Table 1. Genetic conditions that can be diagnosed by each methodology. The current methodology in common practice is marked 
with an asterisk.  
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Advantages
• Characterize entire genomes for full spectrum of 
genetic variants in a single experiment
• Any type of de novo mutation (including balanced 
rearrangements)
• Higher resolution, accuracy and reliability
• Interrogating almost every nucleotide amplified
• Digital precision (not relying on fluorescent intensities)
• Massive sequence data
Challenges
• Reduction in sequencing costs
• Improvements in WGA techniques to avoid bias by artifacts 
and providing reliable complete genome coverage
• Further validation studies for base calling and alignment 
accuracy
• Interpretation of the massive sequence data (e.g.: to 
distinguish background polymorphisms from disease-causing)
• Defining pertinent ethical guide-lines
Protocols favoring NGS
• Multiplex barcode sequencing (Bar-seq): Analyze multiple samples in a single run, 
even from different patients and for different analysis requirements. 
• Small affordable instruments for low-throughput applications, requiring low-coverage 
and focused on target sequencing. 
• Trophectoderm biopsy: Increases the number of cells and DNA. Reduces 
misdiagnosis rate (e.g.: by mosaicism) and number of samples to analyze. 
Third-generation
Figure 3. Types of genome alterations detectable by second-generation sequencing. Edited from 
Meverson et al. (2010). Nature Reviews Genetics.
Advances in 3G will offer:
• Higher throughput
• Longer read lengths
• Higher accuracy
• Less starting DNA
• Faster turnaround time
• Lower cost
